Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

43.62
+0.16000.37%
Post-market: 43.620.00000.00%19:30 EDT
Volume:251.79K
Turnover:10.97M
Market Cap:2.09B
PE:-14.29
High:44.30
Open:44.21
Low:43.01
Close:43.46
52wk High:52.93
52wk Low:22.73
Shares:47.98M
Float Shares:30.39M
Volume Ratio:0.70
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:4.95
PE(LYR):-15.23

Loading ...

Rapport Therapeutics Holds 2026 Annual Shareholder Meeting

TIPRANKS
·
Jun 11

Rapport Therapeutics shareholders elected Class II directors at annual meeting

Reuters
·
Jun 11

Rapport Therapeutics (RAPP) Is Down 9% After Strong RAP-219 Data Outshines Rival Trial - Has The Bull Case Changed?

Simply Wall St.
·
Jun 06

RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy

TIPRANKS
·
Jun 05

BTIG Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jun 02

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $743,673.08

Reuters
·
May 29

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from BTIG

TIPRANKS
·
May 21

Rapport Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
May 21

Rapport Therapeutics to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 21

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

GlobeNewswire
·
May 21

Rapport Therapeutics Coverage Assumed by Truist Securities at Buy

Dow Jones
·
May 20

Rapport Therapeutics assumed with a Buy at Truist

TIPRANKS
·
May 19

Third Rock Ventures V disposes 133,618 Rapport Therapeutics shares for $5.38 million

Reuters
·
May 14

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $11,096,094.77

Reuters
·
May 12

Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG

Dow Jones
·
May 08

Rapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTrading

TIPRANKS
·
May 08

Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile

TIPRANKS
·
May 08

Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market

TIPRANKS
·
May 08

Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)

TIPRANKS
·
May 07

Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07